Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2025 Sep 18. [Epub ahead of print]
Gründer G, Mertens L, Spangemacher M, Schmitz C. [Can antidepressants negatively alter the long-term course of depressive disorders?]. Nervenarzt. 2025 96(2):146-152. Epub 2025 Feb 24.
Spangemacher M, Reinwald J, Adolphi H, Kärtner L, Mertens LJ, Schmitz CN, Gründer G. [Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment]. Nervenarzt. 2025 96(2):119-127. Epub 2025 Jan 16.
Wolff M, Rutrecht H, Mertens L, Meijer AA, Beck J, Pérez S, Gründer G, Dziobek I, Jungaberle H. Common factors in altered states: Understanding psychedelic therapy through the lens of Grawe's general change mechanisms. Psychol Rev. 2025 Oct 9. [Epub ahead of print]
Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Med (New Rochelle). 2025 3(1):1-18.